Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a star medication used to treat non-small-cell lung carcinomas (NSCLCs). It has caused broad public concern that osimertinib has relatively low stability in plasma. We explored why osimertinib...

Full description

Bibliographic Details
Main Authors: Zheng Yuan, Xin Yu, Siyang Wu, Xiaonan Wu, Qiutao Wang, Wenhao Cheng, Weiyu Hu, Chen Kang, Wei Yang, Yingfei Li, Xiao-Yang Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Pharmacology
Subjects:
osimertinib
plasma stability
UPLC-MS/MS
acetonitrile
cysteine
non-small-cell lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.928983/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.928983/full

Similar Items